Navigation Links
Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
Date:7/28/2009

CINCINNATI, July 28 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the realignment of its C-suite to strengthen its competitive position and position the Company for continued growth as a top-tier global CRO. The creation of a new Chief Administrative Officer (CAO) role within Kendle's C-suite and executive leadership team as part of this realignment provides dedicated leadership for strategic technology and infrastructure enhancement initiatives to drive down overhead and deliver increased innovation, productivity and organizational efficiency, strengthening the Company's ability to deliver strategic outsourcing solutions for its global biopharmaceutical customers.

Assuming the new leadership role of Executive Vice President and CAO is Kendle's current Chief Operating Officer (COO), Christopher C. Bergen. Mr. Bergen is a co-founder of Kendle, and served as President and Chief Operating Officer from the Company's founding in June 1981 until April 2008 and as Chief Operating Officer from April 2008 until July 2009. He has more than 30 years of experience in the clinical research industry, with demonstrated expertise in the design and implementation of innovative technology solutions to enhance clinical trial delivery and organizational efficiency. As COO Mr. Bergen has provided executive leadership for Kendle's ERP initiative, the largest initiative in the Company's history, which will yield significant benefits for the organization and its customers, including streamlined global processes, enhanced organizational efficiency and real-time access to clinical trial data to facilitate efficient project management. Kendle currently is in the final stages of implementing the financial components of its ERP.

"As we move forward and position Kendle to compete for higher-level strategic outsourcing opportunities our infrastructure and ability to deliver on a global scale have never been more important," said Candace Kendle, PharmD, Chairman and Chief Executive Officer. "This new executive leadership role and the appointment of our most senior leader to fill it demonstrates Kendle's continued focus on the key business drivers that will support our future growth and meet the strategic outsourcing needs of our customers."

The creation of the CAO role and the appointment of Mr. Bergen complement other recent moves by Kendle to strengthen its executive leadership team. In conjunction with the appointment of Mr. Bergen, Kendle today announced the appointment of former Quintiles executive and 20-year industry veteran Stephen Cutler, PhD, as its new Senior Vice President and COO, providing global leadership for the Company's worldwide Late Stage operations.

In addition, reflecting Kendle's increasing focus on strategic customer relationships, Simon Higginbotham is adding the Chief Marketing Officer (CMO) role to his leadership of the Company's Early Stage business, assuming the title of Senior Vice President and CMO effective immediately.

Additional moves to enhance key strategic roles within the Company's C-suite in recent months include the appointments of Jarrod Pontius as Vice President, Chief Legal Officer and Secretary and the appointment of Keith Cheesman as Senior Vice President and Chief Financial Officer.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
2. Kendle Names Jarrod Pontius Chief Legal Officer
3. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
4. Kendle Announces First Quarter 2009 Results
5. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
6. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
7. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
8. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
9. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
10. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
11. Kendle to Present at the 2008 Credit Suisse Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):